Vaxcyte appoints Dr. Olivier Brandicourt to board of directors

Vaxcyte, Inc.

Appointment effective May 1, 2025 as a Class III director with term expiring at 2026 annual meeting.
Board determined Dr. Brandicourt qualifies as independent under Nasdaq rules.
Receives initial equity award of $800,000 in nonstatutory stock options vesting over 36 months.
Annual cash retainer of $50,000 and annual equity award of $450,000 (75% option, 25% RSU).
Standard indemnification agreement entered; no reportable transactions per Item 404(a).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Olivier Brandicourt

Director

PCVX · Vaxcyte, Inc.

Effective: 2025-05-01
Filed: May 1, 2025, 7:59 PM ET

On May 1, 2025, upon recommendation of the Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed Dr. Olivier Brandicourt to the Board as a Class III director, which appointment became effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Olivier Brandicourt was appointed as Director at Vaxcyte, Inc..

Action: appointed
Role: Director

Exact text from the filing

On May 1, 2025, upon recommendation of the Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed Dr. Olivier Brandicourt to the Board as a Class III director, which appointment became effective immediately.

View on SEC.gov

Vaxcyte, Inc. filing history →

Source: SEC EDGAR

accession 0001649094-25-000057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.